🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Overview of #SCLC at #CIOT25 from Sanjay Popat - chemo + atezo/durva is our 1L approach for ES SCLC. IMforte shows that maintenance lurbinectedin + atezolizumab improves OS and becomes our new standard of care, for now. Tarlatamab our new 2L SOC, will it move to maintenance?

Who said lung cancer exhibits can’t be fun?? Thank you to every nurse who brought their energy, questions, and kindness Lung Cancer Nursing UK Roy Castle Lung Cancer Foundation Ruth Strauss Foundation EGFR Positive Lung Cancer UK UKALK+ Sanjay Popat Tom Newsom-Davis European Lung Foundation American Lung Association UKLCC

3 weeks after ASCO25, let’s digest the data from the landmark DeLLphi-304 trial published in NEJM that changed the >30 years SoC in recurrent #SCLC from immunobiology and clinical standpoints: 🧵 1/15 #some #LCSM @ASCO IASLC ESMO - Eur. Oncology ETOP IBCSG Partners Foundation EORTC SmallCellSMASHERS

We have spent many hrs with the DVLA and our recent publication on Driving with brain mets is the result of all those discussions. If you didn’t get the opportunity to pick up a copy at our stand, please either download a copy at alkpositive.org.uk/_files/ugd/341… or feel free to email us

Rami Manochakian MD, FASCO Cancer Education Oncology Brothers Nathan A. Pennell MD, PhD, FASCO Dr Amol Akhade Hem-Onc Fellows Network gilberto lopes Hidehito HORINOUCHI Aɴᴛᴏɴɪᴏ Pᴀssᴀʀᴏ Eric K. Singhi, MD Narjust Florez, MD, FASCO Grupo Español de Cáncer de Pulmón Aakash Desai, MD, MPH, FASCO Devika Das, MD, MSHQS Jarushka Naidoo Dr. Nagla Abdel Karim Lung Cancers Today Sanjay Popat Tom Newsom-Davis Navneet Singh Balazs Halmos Yakup Ergün Good to hear that more options are available. However, after negative HERTHENA-Lung02 with HER3-DXd with similar preliminary results I will remain cautious. Results of ongoing phase III trial TROPION-Lung 15 will shed light on this competitive indication with many anti-Trop2 ADCs

📣Updated ESMO #ClinicalPracticeGuideline recommendations in oncogene-addicted metastatic #NSCLC: more #TargetedTherapy agents now available in 1L or at resistance. #LungCancer #mNSCLC #ESMOGuidelines 🔗 ow.ly/v7nE50Wbqsf

Very popular workshop, quickly fully booked Research is one of BTOG central tenets. We continue to develop and promote excellence in UK thoracic oncology research

Previous and current BTOG Chairs celebrating RoyCastleLungCancer 35th birthday behind the famous door Lung cancer screening saves lives, and 🇬🇧leads the world, but we must secure its immediate and long-term future Thank you UK Prime Minister for hosting Sanjay Popat

What an incredible impact Roy Castle Lung Cancer Foundation have had over 35 years on improving outcomes for people diagnosed with lung cancer. An honour to celebrate with friends at Downing Street & also discuss the rapid and comprehensive implementation of #lungcancer screening

We have three TKIs: firmonertinib, sunvozertinib, and zipalertinib, with FDA breakthrough designation (BTD) for EGFR Ex20ins NSCLC patients. We will change the SoC landscape soon for this patient population! EGFR Resisters Exon 20 Group, a multistakeholder organization Eric K. Singhi, MD I cannot wait to debate among

Bravo Benjamin Besse! Very welcome news. Looking forward to your Presidency

Phase 3 ALKAZAR study evaluating Neladalkib (NVL-655) is actively enrolling patients with newly diagnosed ALK+ mNSCLC! #HawaiiLung25 DAVA Oncology ALK Positive

CRUK and our partner organisations are delighted to hear Welsh Government will #MakeLungScreeningHappen and introduce a national lung cancer screening programme, expected in 2027, targeted towards those at greatest risk of the disease. Each year, lung cancer claims around 1,800

What is restricted mean survival time? And what does it have to do with replacing an old couch that your pet has torn apart? Find out in a new Stats, STAT! animated video from NEJM Evidence: youtu.be/ZRxG5JmV7e4

ADOPT-lung TiP paper out in Lung Cancer Journal doi.org/10.1016/j.lung… Neo-adjuvant nivolumab has shown sig. OS benefit in CheckMate-816. The need for 1 additional year of adjuvant immunotherapy is being debated. This trial aims to investigate the added value of adjuvant durvalumab

💡Starting out in thoracic oncology? The IASLC Communications Committee proudly brings you: ‘50 Years of Progress in NSCLC: A New Fellow’s Guide in the Clinic’ A whistlestop tour of key advances, distilled by global leaders JTO & JTO CRR OncoAlert #LCSM jto.org/article/S1556-…

A hot July Saturday in London Nothing like a great day Marylebone Cricket Club Set up for a great match and a superb day’s play #INDvsENG

Wonderful who you bump into at Lords. Good to see solid BTOG representation.

Missing you Ben Solomon Prof Tom John

Yes, Lord's Cricket Ground again for D4 of this amazing #INDvsENG match. Discussing all things cricket with superb RMH fellows and future leaders David Cheng, Harriet McGrath Alexius John. Sadly no sight of my cricket sparring partner Clive Peedell